Published in Cell: TRON is part of a 36-member alliance led by the Parker Institute and Cancer Research Institute identifying parameters for better vaccine design in the fight against cancer. As part of TESLA (Tumor Neoantigen Selection Alliance), TRON performed advanced computational analysis on samples from melanoma and non-small cell lung cancer to identify characteristics
Multi-omics characterization of the 4T1 murine mammary gland tumor model
The murine mammary carcinoma cell line 4T1 is a widely used syngeneic tumor model for human breast cancer and specifically triple-negative breast cancer (TNBC). Profiling tumor models is important to translate pre-clinical findings appropriately. The authors aimed to complement the evaluation of 4T1 as adequate breast cancer or even TNBC model. Analysis of the whole-exome
A liposomal RNA vaccine augments the antitumor activity of local radiotherapy in mice
TRON is delighted to announce the publication of a scientific article in OncoImmunology.
TRON wears white for A Future #Immune2Cancer
TRON is proud to join the Cancer Research Institute this June 12 in bringing global awareness about the life-saving potential of cancer immunotherapy. By wearing white together, we are driving the future of immune-based science and medicine for cancer treatments, and ultimately, cures. Learn more about TRON’s mission and work at www.tron-mainz.de.
PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation
TRON is delighted to announce a scientific article published in Oncotarget.
TRON’s activities against the Coronavirus pandemic
As an innovative immunological research institute, TRON was asked by a renowned industrial partner to support the development of a vaccine against the currently pandemic coronavirus with preclinical studies.
Dr. Luisa Bresadola awarded BMS Young Scientist prize
We are delighted to announce that TRON scientist Dr. Luisa Bresadola has won the Bristol-Myers-Squibb Young Scientist award in the field of immune-oncology! Luisa’s work comprises analysis of head and neck squamous cell carcinoma next-generation sequencing data, generated by TRON in collaboration with the University of Birmingham, to determine tumor evoluation in this cancer entity.
Miteinander gut leben – Rheinland-Pfalz gegen Hass und Hetze
TRON unterstützt das Anliegen der Landesregierung und tritt gemeinsam mit der Landesregierung für unsere Grundwerte ein. Nur gemeinsam können wir zeigen, dass die Mehrheit für Respekt und gegen Hass steht. „Rheinland-Pfalz ist ein lebenswertes und weltoffenes Land. Das wollen wir auch in Zukunft sein. Deshalb finden wir uns nicht damit ab, dass der Umgang auf
An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors.
Although chimeric antigen receptor (CAR)-modified T cells (CAR T-cells) have been shown to be effective against hematological malignancies, evidence of their potential against immune-suppressive solid tumors is missing. Key challenges for this include the selection of tumor-specific targets and the persistence of CAR-T cells upon adoptive transfer. In this study, teams from Biontech and TRON
Top 20 Translational Researchers (2018)
Mainz, December 9, 2019 – TRON founders Ugur Sahin and Özlem Türeci have been named among the Top 20 Translational Researchers (2018) for the 2nd time by Nature Biotechnology. Nature Biotechnology’s ranking is based on the number of total patents (US and European) awarded, the researcher’s top-cited patent over the past 5 years and
BioNTech IPO
TRON congratulates its cooperation Partner BioNTech SE on its successful IPO!
TRON scientists publish in Molecular Therapy
Mainz, September 27, 2019 – TRON scientists publish in Molecular Therapy TRON has published an article on a novel RNA-based vector for antigen delivery in Molecular Therapy. Among the exciting results, the authors show that trans-amplifying RNA as a vaccine vector induces protective immune responses against influenza challenge in mice, at a 400x lower dose
